Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

IMPORTANCE: The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. OBJECTIVE: To evaluate the efficacy and safety of inotuzumab ozogamicin pl...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Oncol
Главные авторы: Jabbour, Elias, Ravandi, Farhad, Kebriaei, Partow, Huang, Xuelin, Short, Nicholas J., Thomas, Deborah, Sasaki, Koji, Rytting, Michael, Jain, Nitin, Konopleva, Marina, Garcia-Manero, Guillermo, Champlin, Richard, Marin, David, Kadia, Tapan, Cortes, Jorge, Estrov, Zeev, Takahashi, Koichi, Patel, Yogin, Khouri, Maria R., Jacob, Jovitta, Garris, Rebecca, O’Brien, Susan, Kantarjian, Hagop
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2017
Предметы:
Brief Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838597/
https://ncbi.nlm.nih.gov/pubmed/28859185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2380
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы